{"id":"NCT03123939","sponsor":"Novartis Pharmaceuticals","briefTitle":"Phase III B in Acute Lymphoblastic Leukemia","officialTitle":"Phase IIIb Study for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-24","primaryCompletion":"2020-10-13","completion":"2020-10-13","firstPosted":"2017-04-21","resultsPosted":"2021-07-21","lastUpdate":"2021-07-21"},"enrollment":69,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Lymphoblastic Leukemia"],"interventions":[{"type":"BIOLOGICAL","name":"CTL019","otherNames":[]}],"arms":[{"label":"CTL019","type":"EXPERIMENTAL"}],"summary":"This is a single arm, open-label, multi-center, phase III B study to determine the safety and efficacy of CTL019 in pediatric/young adult patients with r/r B-cell Acute Lymphoblastic Leukemia (ALL).","primaryOutcome":{"measure":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"From CTL019 infusion until end of study, up to 12 months","effectByArm":[{"arm":"CTL019","deltaMin":69,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Austria","Belgium","Canada","France","Germany","Italy","Japan","Norway","Spain"]},"refs":{"pmids":["35422096"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":50,"n":69},"commonTop":["Cytokine release syndrome","Pyrexia","Hypogammaglobulinaemia","Diarrhoea","Nausea"]}}